A Phase IIb Randomised, Double Blind, Placebo Controlled Parallel Group Study To Investigate The Efficacy And Safety Of PF-00610355 Over 4 Weeks In Moderately Asthmatic Subjects.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2013
At a glance
- Drugs PF 610355 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 07 Nov 2011 Planned patient number is 356 according to European Clinical Trials Database.
- 14 Mar 2011 Last checked against ClinicalTrials.gov record.
- 14 Mar 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.